CTNNB1 and head and neck squamous cell carcinoma: Since CTNNB1/β-CATENIN was overexpressed in patients with good prognosis, potential therapies tailored toward β-CATENIN-expressing cells, such as PRI-724 (a small molecule inhibitor of the interaction between CBP and β-CATENIN), might be a viable option for treatment de-escalation for these HPV-positive HNSCC patients (Zhang and Wang 2020).